Daily Stock Analysis, CVM, CEL-SCI Corp, priceseries

CEL-SCI Corp. Daily Stock Analysis
Stock Information
Open
12.65
Close
12.00
High
12.68
Low
11.90
Previous Close
12.72
Daily Price Gain
-0.72
YTD High
18.00
YTD High Date
May 4, 2020
YTD Low
6.35
YTD Low Date
Feb 26, 2020
YTD Price Change
2.91
YTD Gain
32.01%
52 Week High
18.00
52 Week High Date
May 4, 2020
52 Week Low
6.00
52 Week Low Date
Oct 24, 2019
52 Week Price Change
3.06
52 Week Gain
34.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
2.04
Jan 18. 2017
2.97
8 Trading Days
45.51%
Link
LONG
Feb 9. 2017
3.00
Feb 16. 2017
3.19
5 Trading Days
6.25%
Link
LONG
Aug 11. 2017
2.31
Aug 18. 2017
2.44
5 Trading Days
5.52%
Link
LONG
Jan 22. 2018
2.20
Jan 25. 2018
2.35
3 Trading Days
6.59%
Link
LONG
Apr 10. 2018
1.64
May 15. 2018
2.64
25 Trading Days
61.20%
Link
LONG
Aug 17. 2018
1.18
Sep 13. 2018
3.09
18 Trading Days
161.48%
Link
LONG
Mar 28. 2019
3.20
Apr 30. 2019
6.41
22 Trading Days
100.38%
Link
LONG
Jun 7. 2019
4.69
Jul 10. 2019
8.19
22 Trading Days
74.55%
Link
LONG
Sep 12. 2019
7.64
Oct 2. 2019
8.82
14 Trading Days
15.44%
Link
LONG
Nov 13. 2019
7.12
Nov 25. 2019
7.51
8 Trading Days
5.43%
Link
LONG
Dec 16. 2019
7.93
Dec 26. 2019
8.51
7 Trading Days
7.28%
Link
LONG
Jan 15. 2020
9.10
Jan 31. 2020
12.29
11 Trading Days
35.04%
Link
LONG
Mar 6. 2020
13.75
Mar 9. 2020
14.79
1 Trading Days
7.60%
Link
LONG
Apr 21. 2020
11.43
May 4. 2020
14.23
9 Trading Days
24.52%
Link
Company Information
Stock Symbol
CVM
Exchange
NYSE MKT
Company URL
http://www.cel-sci.com
Company Phone
7035069460
CEO
Geert R. Kersten
Headquarters
Virginia
Business Address
8229 BOONE BLVD ., SUITE 802, VIENNA, VA 22182
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000725363
About

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Description

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.